REVIEW
Medication-Related Osteonecrosis of the Jaw Caused by Drugs With Antiangiogenic Effects—What Should the Clinician Be Aware of and What Course of Treatment Can Be Applied? A Systematic Review of Case Series and Case Reports
Francisca Jennifer Duarte de Oliveira,
Moan Jéfter Fernandes Costa,
Carla Samily de Oliveira Costa,
Lélia Batista de Souza,
Corresponding Author
Francisca Jennifer Duarte de Oliveira
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Correspondence:
Francisca Jennifer Duarte de Oliveira ([email protected])
Search for more papers by this authorMoan Jéfter Fernandes Costa
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorCarla Samily de Oliveira Costa
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorLélia Batista de Souza
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorFrancisca Jennifer Duarte de Oliveira,
Moan Jéfter Fernandes Costa,
Carla Samily de Oliveira Costa,
Lélia Batista de Souza,
Corresponding Author
Francisca Jennifer Duarte de Oliveira
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Correspondence:
Francisca Jennifer Duarte de Oliveira ([email protected])
Search for more papers by this authorMoan Jéfter Fernandes Costa
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorCarla Samily de Oliveira Costa
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorLélia Batista de Souza
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
Search for more papers by this authorFirst published: 26 November 2024
Funding: The authors received no specific funding for this work.
ABSTRACT
Objective
This systematic review aimed to summarise the most common drugs with antiangiogenic effects associated with MRONJ, the diseases that patients can present and discuss the appropriate course of treatment.
Materials and Methods
PubMed, Web of Science, Scopus and Embase were screened for case reports up to February 2024. Two independent reviewers selected the articles in a two-step selection, screening 1.327 articles. The final sample was composed of 32 articles.
Results
Most of the patients were male with a mean age of 58 years. Although the majority of patients had cancer, 20% were treated with drugs with antiangiogenic effects for other diseases. The lesions occurred mainly in the posterior mandible, with dental extraction associated in more than half of the cases. Antibiotic treatment was employed in most cases with amoxicillin and clavulanic acid, usually associated with 0.12% chlorhexidine or a 0.2% oral rinse. Bevacizumab was the medication most associated with the lesions (40%).
Conclusion
The dental community needs to be aware of the new drugs that can cause MRONJ through antiangiogenic effects, given that new medications are being reported every day.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- 1R. E. Marx, “Pamidronate (Aredia) and Zoledronate (Zometa) Induced Avascular Necrosis of the Jaws: A Growing Epidemic,” Journal of Oral and Maxillofacial Surgery 61 (2003): 1115–1117.
- 2S. L. Ruggiero, T. B. Dodson, J. Fantasia, et al., “American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update,” Journal of Oral and Maxillofacial Surgery 72 (2014): 1938–1956.
- 3R. Landesberg, V. Woo, S. Cremers, et al., “Potential Pathophysiological Mechanisms in Osteonecrosis of the Jaw,” Annals of the New York Academy of Sciences 1218 (2011): 62–79.
- 4M. R. Allen and D. B. Burr, “The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data,” Journal of Oral and Maxillofacial Surgery 67 (2009): 61–70.
- 5M. Troeltzsch, T. Woodlock, S. Kriegelstein, T. Steiner, K. Messlinger, and M. Troeltzsch, “Physiology and Pharmacology of Nonbisphosphonate Drugs Implicated in Osteonecrosis of the Jaw,” Journal of the Canadian Dental Association 78 (2012): c85.
- 6G. Favia, A. Tempesta, L. Limongelli, et al., “A Case of Osteonecrosis of the Jaw in a Patient With Crohn's Disease Treated With Infliximab,” American Journal of Case Reports 18 (2017): 1351–1356.
- 7S. Samieirad, A. Labafchi, K. Famili, and H. Hashemzadeh, “Medication-Related Osteonecrosis of the Jaw (MRONJ) Due to Simvastatin: An Unusual Case Report,” World Journal of Plastic Surgery 10 (2021): 132–135.
- 8M. A. Almousa, G. K. Alharbi, A. S. Alqahtani, Y. Chachar, L. Alkadi, and A. Aboalela, “Dental practitioners' and students' Knowledge of Medication Related Osteonecrosis of the Jaw (MRONJ),” Saudi Pharmaceutical Journal: SPJ: The Official Publication of the Saudi Pharmaceutical Society 29 (2021): 96–103.
- 9B. Galis, J. Zajko, D. Hirjak, et al., “Is the Prevalence of the Medication-Related Osteonecrosis of the Jaws Underestimated, Evaluation in Oncological and Non-Oncological Disease,” Bratislavské Lekárske Listy 118 (2018): 724–731.
- 10D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement,” PLoS Medicine 6 (2009): e1000097.
- 11J. Higgins, J. Thomas, J. Chandler, et al., Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (London, UK: Cochrane, 2020). Available from https://www.training.cochrane.org/handbook.
- 12D. Altman, “Practical Statistics for Medical Research,” Lyon 2 (1993): 404.
- 13J. J. Gagnier, G. Kienle, D. G. Altman, D. Moher, H. Sox, and D. Riley, “Checklist for Case Reports,” Crit Apprais Checkl Case Reports 53 (2013): 1541–1547.
- 14S. Akkach, L. Shukla, and D. Morgan, “Everolimus-Induced Osteonecrosis of the Jaw in the Absence of Bisphosphonates: A Case Report,” British Journal of Oral & Maxillofacial Surgery 57 (2019): 688–690.
- 15G. Bettini, S. Blandamura, G. Saia, and A. Bedogni, “Bevacizumab-Related Osteonecrosis of the Mandible Is a Self-Limiting Disease Process,” BML Case Reports 2012 (2012): bcr2012007284, https://doi.org/10.1136/bcr-2012-007284.
10.1136/bcr-2012-007284 Google Scholar
- 16P. B. Binello, R. Bandelloni, M. Labanca, B. Buffoli, R. Rezzani, and L. F. Rodella, “Osteonecrosis and the Jaws and Bevacizumab Therapy: A Case Report,” International Journal of Immunopathology and Pharmacology 25 (2012): 789–791.
- 17F. Erovigni, A. Gambino, M. Cabras, et al., “Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated With Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases,” Dental Journal 4 (2016): 39.
10.3390/dj4040039 Google Scholar
- 18C. L. Estilo, M. Fornier, A. Farooki, D. Carlson, G. Bohle, and J. M. Huryn, “Osteonecrosis of the Jaw Related to Bevacizumab,” Journal of Clinical Oncology 26 (2008): 4037–4038.
- 19Y. Fleissig, E. Regev, and H. Lehman, “Sunitinib Related Osteonecrosis of Jaw: A Case Report,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 113 (2012): e1–e3.
- 20F. Garuti, V. Camelli, L. Spinardi, L. Bucci, and F. Trevisani, “Osteonecrosis of the Jaw During Sorafenib Therapy for Hepatocellular Carcinoma,” Tumori 102 (2016): S69–S70.
- 21S. Greuter, F. Schmid, T. Ruhstaller, and B. Thuerlimann, “Bevacizumab-Associated Osteonecrosis of the Jaw,” Annals of Oncology 19 (2008): 2091–2092.
- 22L. Gupta, K. Dholam, Y. Janghel, and S. V. Gurav, “Osteonecrosis of the Jaw Associated With Imatinib Therapy in Myeloproliferative Neoplasm: A Rare Case Report,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 00 (2020): 1–6.
- 23R. N. Hopp, J. Pucci, A. R. Santos-Silva, and J. Jorge, “Osteonecrosis After Administration of Intravitreous Bevacizumab,” Journal of Oral and Maxillofacial Surgery 70 (2012): 632–635.
- 24T. Y. Jung, “Osteonecrosis of Jaw After Antiangiogenic Agent Administration in a Renal Cell Carcinoma Patient,” Oral and Maxillofacial Surgery Cases 3 (2017): 27–33.
10.1016/j.omsc.2017.03.001 Google Scholar
- 25F. P. Koch, C. Walter, T. Hansen, E. Jäger, and W. Wagner, “Osteonecrosis of the Jaw Related to Sunitinib,” Oral and Maxillofacial Surgery 15 (2011): 63–66.
- 26M. Magremanne, M. Lahon, J. De Ceulaer, and H. Reychler, “Unusual Bevacizumab-Related Complication of an Oral Infection,” Journal of Oral and Maxillofacial Surgery 71 (2013): 53–55.
- 27G. Maluf, R. J. Caldas, E. R. Fregnani, and P. S. da Silva Santos, “A Rare Case of Bevacizumab-Related Osteonecrosis of the Jaw Associated With Dental Implants,” International Journal of Implant Dentistry 5 (2019): 4–9.
- 28R. Marino, F. Orlandi, F. Arecco, S. Gandolfo, and M. Pentenero, “Osteonecrosis of the Jaw in a Patient Receiving Cabozantinib,” Australian Dental Journal 60 (2015): 528–531.
- 29R. Mauceri, V. Panzarella, I. Morreale, and G. Campisi, “Medication-Related Osteonecrosis of the Jaw in a Cancer Patient Receiving Lenvatinib,” International Journal of Oral and Maxillofacial Surgery 48 (2019): 1530–1532.
- 30Z. Mihaylova, R. Ugrinov, E. Aleksiev, and P. Stanimirov, “Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports,” Acta Medica Bulgarica 46 (2019): 51–56.
10.2478/amb-2019-0019 Google Scholar
- 31L. Monteiro, C. Vasconcelos, J. Pacheco, and F. Salazar, “Photobiomodulation Laser Therapy in a Lenvatinib-Related Osteonecrosis of the Jaw: A Case Report,” Journal of Clinical and Experimental Dentistry 13 (2021): e626–e629.
- 32Y. Myoken, Y. Fujita, R. Imanaka, and S. Toratani, “Bosutinib-Induced Osteonecrosis of the Jaw in a Patient With Chronic Myeloid Leukemia: A Case Report,” Oral and Maxillofacial Surgery 25 (2021): 421–425.
- 33O. Nicolatou-Galitis, M. Migkou, A. Psyrri, et al., “Gingival Bleeding and Jaw Bone Necrosis in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: Report of 2 Cases With Clinical Implications,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 113 (2012): 234–238.
- 34I. Oz, I. Kaplan, S. Kleinman, S. Arbel, and A. Shuster, “Medication-Related Osteonecrosis of the Jaws Associated With Intravitreal Administration of Ranibizumab,” International Journal of Oral and Maxillofacial Surgery 49 (2020): 1589–1591.
- 35D. Pakosch, D. Papadimas, J. Munding, D. Kawa, and M. S. Kriwalsky, “Osteonecrosis of the Mandible due to Anti-Angiogenic Agent, Bevacizumab,” Oral and Maxillofacial Surgery 17 (2013): 303–306.
- 36E. Papadopoulou, E. Vardas, S. Tziveleka, et al., “Oral Side Effects in Patients With Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases,” Dental Journal 10 (2022): 232, https://doi.org/10.3390/dj10120232.
10.3390/dj10120232 Google Scholar
- 37A. Ponzetti, F. Pinta, R. Spadi, et al., “Jaw Osteonecrosis Associated With Aflibercept, Irinotecan and Fluorouracil: Attention to Oral District,” Tumori 102 (2016): S74–S77.
- 38A. R. Santos-Silva, G. A. Belizário Rosa, G. D. Castro Júnior, R. B. Dias, A. C. Prado Ribeiro, and T. B. Brandão, “Osteonecrosis of the Mandible Associated With Bevacizumab Therapy,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 115 (2013): e32–e36.
- 39M. Sato, F. Ono, A. Yamamura, and S. Onochi, “A Case of Osteonecrosis of the Jaw During Treatment by Bevacizumab for Sigmoid Colon Cancer,” Nihon Shokakibyo Gakkai Zasshi 110 (2013): 655–659.
- 40A. Singh, A. Pischek, J. R. Randazzo, et al., “Ramucirumab-Related Osteonecrosis of the Jaw,” Oral Oncology 125 (2022): 105660.
- 41L. Sisalli, F. Giordano, A. Chiacchio, A. Acerra, and M. Caggiano, “Medication-Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab,” Case Reports in Dentistry 2023 (2023): 1–8.
10.1155/2023/5544285 Google Scholar
- 42T. Takahara, K. Shimada, S. Ishida, et al., “Osteonecrosis of the Jaw Associated With Receiving Sunitinib Monotherapy: A Rare Case,” Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology 33 (2021): 66–70.
10.1016/j.ajoms.2020.08.005 Google Scholar
- 43P. Zarringhalam, E. Brizman, and K. Shakib, “Medication-Related Osteonecrosis of the Jaw Associated With Aflibercept,” British Journal of Oral & Maxillofacial Surgery 55 (2017): 314–315.
- 44N. Tanna, C. Steel, S. Stagnell, and E. Bailey, “Awareness of Medication Related Osteonecrosis of the Jaws (MRONJ) Amongst General Dental Practitioners,” British Dental Journal 222 (2017): 121–125.
- 45E. Vigarios, J. B. Epstein, and V. Sibaud, “Oral Mucosal Changes Induced by Anticancer Targeted Therapies and Immune Checkpoint Inhibitors,” Supportive Care in Cancer 25 (2017): 1713–1739.
- 46A. Sawano, S. Iwai, Y. Sakurai, et al., “Flt-1, Vascular Endothelial Growth Factor Receptor 1, Is a Novel Cell Surface Marker for the Lineage of Monocyte-Macrophages in Humans,” Blood 97 (2001): 785–791.
- 47B. Barleon, S. Sozzani, D. Zhou, H. A. Weich, A. Mantovani, and D. Marmé, “Migration of Human Monocytes in Response to Vascular Endothelial Growth Factor (VEGF) is Mediated via the VEGF Receptor Flt-1,” Blood 87 (1996): 3336–3343.
- 48P. Boffano, A. M. Agnone, F. Neirotti, et al., “Epidemiology, Etiopathogenesis, and Management of MRONJ: A European Multicenter Study,” Journal of Stomatology, Oral and Maxillofacial Surgery 125 (2024): 101931, https://doi.org/10.1016/j.jormas.2024.101931.31.
- 49A. Eguia, L. Bagán-Debón, and F. Cardona, “Review and Update on Drugs Related to the Development of Osteonecrosis of the Jaw,” Medicina Oral, Patología Oral y Cirugía Bucal 25, no. 1 (2020): e71–e83, https://doi.org/10.4317/medoral.23191.
- 50J. Fangusaro, S. Gururangan, R. I. Jakacki, et al., “Bevacizumab-Associated Osteonecrosis of the Wrist and Knee in Three Pediatric Patients With Recurrent CNS Tumors,” Journal of Clinical Oncology 31 (2013): e24–e27.
- 51L. J. C. Oliveira, F. S. N. A. Canedo, K. P. Sacardo, et al., “Bevacizumab-Associated Osteonecrosis of the Femur and Tibia,” Oxford Medical Case Reports 2015 (2019): omz040, https://doi.org/10.1093/omcr/omz040.
10.1093/omcr/omz040 Google Scholar
- 52S. Rutella, G. Fiorino, S. Vetrano, et al., “Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease,” American Journal of Gastroenterology 106 (2011): 762–770.
- 53F. P. Cantatore, N. Maruotti, A. Corrado, and D. Ribatti, “Anti-Angiogenic Effects of Biotechnological Therapies in Rheumatic Diseases,” Biologics: Targets and Therapy 11 (2017): 123–128.
- 54X. Y. Zhu, E. Daghini, A. R. Chade, et al., “Disparate Effects of Simvastatin on Angiogenesis During Hypoxia and Inflammation,” Life Sciences 83 (2008): 801–809.
- 55L. Zebic and V. Patel, “Preventing Medication-Related Osteonecrosis of the Jaw,” BMJ 365 (2019): l1733, https://doi.org/10.1136/bmj.l1733.
- 56A. A. Khan, A. Morrison, D. A. Hanley, et al., “Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus,” Journal of Bone and Mineral Research 30 (2015): 3–23.
- 57O. Di Fede, V. Panzarella, R. Mauceri, et al., “The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention,” BioMed Research International 2018 (2018): 1–10.
- 58M. Forte, A. d'Amati, L. Limongelli, et al., “Could MRONJ be Related to Osimertinib Monotherapy in Lung Cancer Patients After Denosumab Suspension?,” Healthcare (Basel) 10 (2024): 12–457.
- 59R. Yan, R. Jiang, L. Hu, Y. Deng, J. Wen, and X. Jiang, “Establishment and Assessment of Rodent Models of Medication-Related Osteonecrosis of the Jaw (MRONJ),” International Journal of Oral Science 10 (2022): 14–41.
- 60A. Bedogni, V. Fusco, A. Agrillo, and G. Campisi, “PROMaF Protocol: Prevention and Research on Medication-Related Osteonecrosis of the Jaws,” Journal of Stomatology, Oral and Maxillofacial Surgery 115 (2014): 223–229.
- 61D. Govaerts, F. Piccart, A. Ockerman, R. Coropciuc, C. Politis, and R. Jacobs, “Adjuvant Therapies for MRONJ: A Systematic Review,” Bone 141 (2020): 115676.
